耐赋康被强仿，引发资本市场担忧。2025年12月，云顶新耀股价累计跌幅两成多，至今，股价还未收复 失地。 耐赋康也是云顶新耀收入的主要来源。根据云顶新耀此前披露的信息，耐赋康在2025年前三季度销售额 已突破10亿元。 目前云顶新耀也在发力其他新产品。今年2月份，该公司也宣布，国家药监局已批准维适平（精氨酸艾 曲莫德片）的新药上市许可申请，用于治疗对传统治疗或生物制剂应答不充分、失应答或不耐受的中度 至重度活动性溃疡性结肠炎成人患者。该药的上市，为中重度活动性溃疡性结肠炎成人患者提供新的治 疗选择。 当天，云顶新耀宣布耐赋康专利维权取得关键进展。广州知识产权法院已于2026年2月26日作出民事裁 定书，全面支持公司提出的诉前行为保全申请，并责令相关仿制药企业立即停止侵权行为并停止挂网， 该裁定自作出之日起立即执行。 云顶新耀的耐赋康是一款原研产品，于2019年6月从瑞典Calliditas公司引入，并于2023年11月获得中国 药监局批准上市，用于治疗具有进展风险的原发性IgA肾病成人患者，填补了中国从疾病源头治疗IgA 肾病的空白。 耐赋康在中国的专利权有效期直至2029年5月7日才到期，但2025年12月 ...

Core Viewpoint - Frontier Biotech has entered into an exclusive licensing agreement with GlaxoSmithKline (GSK) for two small RNA (siRNA) pipeline products, which includes a candidate drug that has reached the IND stage and another that is still in preclinical phase [1][2] Financial Aspects - Frontier Biotech will receive an upfront payment of $40 million and a milestone payment of $13 million, with potential additional milestone payments totaling up to $950 million for the two projects [1] - The company's market capitalization is approximately 9.3 billion yuan, with a stock price increase of 9.29% on the day of the announcement, closing at 24.7 yuan per share [2] - Financial data indicates that Frontier Biotech's revenue is projected to grow from 40 million yuan in 2020 to 120 million yuan in 2024, but the company has accumulated losses exceeding 1.7 billion yuan [5][7] Product Development - The collaboration with GSK allows Frontier Biotech to manage early development work, including Phase I clinical trials in China, while GSK will handle global clinical development and commercialization [1][2] - The specific project codes for the licensed products have not been disclosed, but one candidate drug for IgA nephropathy has reached the IND stage [2][3] Strategic Positioning - The partnership with GSK is seen as a means to improve cash flow for Frontier Biotech, which has faced cash pressure due to high R&D expenses and limited commercial success from its existing products [5][7] - The company has shifted its focus to small RNA drugs after previously developing HIV treatments, indicating a strategic pivot in response to market conditions [7][10] Industry Context - The small RNA drug sector is gaining attention, with potential applications targeting pathogenic genes, although technical challenges remain, particularly in non-liver delivery systems [11] - The market for small RNA drugs is expected to grow, with several products in clinical stages for various indications, including hepatitis B and hypertension [11]

Investment Rating - The report indicates a positive investment outlook for the IgA nephropathy drug market, transitioning from "no drugs available" to "multiple drugs available" [2]. Core Insights - IgA nephropathy (IgAN) is one of the most common primary glomerulonephritis globally and particularly prevalent in China, with a national prevalence rate of 39.73% among primary glomerulonephritis patients [25]. - The global drug development landscape for IgAN is concentrated in late-stage clinical trials, with significant interest from multinational pharmaceutical companies in the Chinese market [36]. - There are currently 6 approved drugs, 1 NDA drug, 10 drugs in Phase III trials, 19 in Phase II, 11 in Phase I, and 8 in IND status globally [6]. Summary by Sections Part 1: Overview of IgA Nephropathy - IgA nephropathy is characterized by the deposition of IgA in the mesangial area of the glomeruli, leading to inflammation and potential kidney damage [10][12]. - The disease's pathogenesis is based on the "four-hit hypothesis," which outlines a sequence of events leading to clinically significant disease [20]. - The average age of diagnosis for IgAN patients in China is around 34 years, with a male-to-female ratio of approximately 58.67% to 41.33% [25]. Part 2: Drug Development for IgA Nephropathy - The report highlights a robust pipeline for IgA nephropathy treatments, with a focus on targeting the first and fourth hits in the disease mechanism [36][37]. - Notable drugs in development include Budesonide, which targets abnormal IgA1 glycosylation, and various monoclonal antibodies aimed at different pathways involved in IgAN [40][43]. - The Chinese drug development landscape mirrors global trends, with a significant number of products expected to enter the market in the coming years [36]. Part 3: Market Situation of Approved IgA Nephropathy Drugs - The market for IgA nephropathy drugs has rapidly expanded, with many products launched in recent years, indicating a shift towards a competitive landscape [73]. - The report emphasizes the importance of the Chinese market, where drugs like Acetylcysteine and Budesonide have seen swift approvals following their global launches [36]. - The competitive dynamics are expected to intensify as more treatments become available, transitioning the market from limited options to a variety of therapeutic choices [36].

Core Viewpoint - Hainan Huirui Pharmaceutical has received approval for the first domestic generic version of Budesonide enteric-coated capsules, breaking the monopoly of Cloudy New Yao in the IgAN treatment market and reshaping the competitive landscape in this field [1][13]. Group 1: Product Approval and Market Impact - Budesonide enteric-coated capsules are an innovative oral targeted delayed-release formulation for treating adult patients with primary IgA nephropathy at risk of progression, filling a gap in domestic treatment options [5]. - The original developer of Budesonide is Calliditas, which granted Cloudy New Yao commercialization rights in Greater China and Singapore in 2019. The product was approved for domestic sale on November 21, 2023, under the brand name "Naifukang" [6]. - Budesonide enteric-coated capsules are set to be included in the medical insurance reimbursement list starting January 1, 2025 [6]. Group 2: Sales Performance and Market Position - In the first seven months post-launch, Naifukang contributed 353 million yuan in revenue to Cloudy New Yao, marking a year-on-year increase of 1581% and accounting for half of the company's total sales [9]. - Sales of Budesonide-related formulations in hospitals nationwide are expected to exceed 4.5 billion yuan in the first half of 2025, with the enteric-coated capsules ranking among the top five products in the nephrology field [9][12]. Group 3: Competitive Landscape and Future Prospects - Currently, only Everest Medicines has been approved to import Budesonide, while Hainan Huirui has secured the first domestic generic approval, challenging Cloudy New Yao's market dominance [13]. - Other companies, including Qilu Pharmaceutical and Shijiazhuang Yaozhu Pharmaceutical, have also submitted applications for generic versions, which are under review [13]. - Budesonide enteric-coated capsules have been recommended in multiple authoritative treatment guidelines due to their innovative mechanism and clinical advantages [16]. - The patent for Budesonide is set to expire in May 2029, allowing for the potential entry of more generics into the market unless patent extensions are granted [16].

Investment Rating - The report maintains an investment rating of "Outperform" [5] Core Insights - The innovative drug sector is experiencing rapid growth, with several new drugs being quickly incorporated into the medical insurance directory as of October 2025 [3][20] - The report highlights significant increases in the number of drugs entering hospitals, particularly those newly included in the insurance directory, indicating strong market demand [3][19] Weekly New Drug Market Review - From November 24 to November 30, 2025, the top five performing new drug companies were: Frontline Bio (+23.12%), Yifang Bio (+15.74%), Rongchang Bio (+15.39%), Kangfang Bio (+14.86%), and Jakes (+14.18%). The five companies with the largest declines were: Yongtai Bio (-4.11%), Nothland (-3.33%), Junshengtai (-2.78%), Boan Bio (-2.09%), and Dongyao Pharma (-1.11%) [1][14] Suggested Focus Stocks - The report suggests focusing on several companies with promising catalysts, including: 1. Companies with MNC certification and high overseas sales potential: Sanofi, Lianbang Pharma, and Kelun Biotech 2. Companies with overseas data catalysts: Betta Pharma, Hutchison China MediTech, and Yimeng Bio 3. Potential heavyweights for overseas MNC licensing: Fuhong Hanlin, Shiyao Group, and Yifang Bio 4. New innovative drug technology breakthroughs: small nucleic acids, in vivo CAR-T, fat reduction and muscle gain, autoimmune CAR-T/bispecific antibodies, and gene therapy [2][18] New Drug Industry Key Analysis - The National Healthcare Security Administration updated the data on innovative drugs included in the insurance directory as of October 2025, showing rapid hospital entry for several newly included domestic innovative drugs. Notable drugs with fast entry rates include: - Hengrui Medicine's Tazobactam - Innovent Biologics' Toripalimab - Haisco's Alogliptin and Clopidogrel - Sinopharm's Aliskiren and Amlodipine - Shanghai Yizhong's Paclitaxel polymer micelles - Kangfang Bio's Ivoris monoclonal antibody [3][19] New Drug Approval and Acceptance Status - This week, 11 new drugs or new indications received approval for market entry, while 13 new drugs or new indications were accepted for review [4][24] New Drug Clinical Application Approval and Acceptance Status - This week, 54 new drug clinical applications were approved, and 44 new drug clinical applications were accepted [8][27]

Core Viewpoint - Qilu Pharmaceutical has submitted a listing application for the generic drug Budesonide enteric-coated capsules, which has been accepted by the CDE, marking a significant step in the competitive landscape for this medication in China [1][12]. Company Summary - Qilu Pharmaceutical is actively pursuing the development of Budesonide enteric-coated capsules, which is the first generic version of this drug in the domestic market [1][7]. - The company has over 35 products currently under review, with more than 20 of these submitted this year, indicating a robust pipeline and commitment to expanding its product offerings [10][12]. - If approved, Budesonide enteric-coated capsules will be the first generic version in China, potentially positioning Qilu as a leader in this therapeutic area [12]. Industry Summary - Budesonide is a glucocorticoid with anti-inflammatory properties, and its inhalation formulations have seen significant sales, with over 5.3 billion yuan in sales expected in 2024, reflecting a year-on-year growth of 31.94% [4][6]. - The market for Budesonide enteric-coated capsules is anticipated to grow, especially with the recent approval of this formulation for IgA nephropathy, making it the only drug approved for this indication in China [4][12]. - Currently, only the original drug is available in the market, creating a competitive environment as multiple companies, including Qilu, Hainan Huirui Pharmaceutical, and Shijiazhuang Yiling Pharmaceutical, have submitted applications for the same generic product [7][10].

Core Insights - The introduction of 75 new drugs has led to significant policy benefits, with over 15,000 settlements and nearly 13 million yuan in fund expenditures in the first month, achieving a reimbursement rate of 67.67% [1] Group 1: Policy Implementation - The Guangxi Medical Insurance Bureau has expanded the "single-column mechanism" for outpatient payment, marking a shift from pilot exploration to institutional normalization [1] - The new policy aims to address urgent public health needs and improve the accessibility of high-cost medications for chronic and rare diseases [1][2] Group 2: Drug Categories - The newly added drugs can be categorized into three types: common medications for chronic diseases, specialized drugs for conditions like multiple sclerosis and cancer, and traditional Chinese medicine [2] - The total number of drugs under the "single-column mechanism" has reached 147, including 44 rare disease medications [2] Group 3: Financial Implications - The estimated annual increase in medical insurance fund expenditure due to the new drugs is approximately 232 million yuan [4] - Under the "single-column mechanism," reimbursement rates vary: 50% for resident insurance, 70% for employed individuals, and 75% for retirees, with annual caps set at 40,000 yuan for residents and 80,000 yuan for employees [2] Group 4: Patient Experience - Patients can now obtain medications directly from outpatient services or pharmacies without hospitalization, significantly enhancing convenience [3]

Core Viewpoint - The supply of Budesonide enteric-coated capsules, a key product of the innovative pharmaceutical company Cloudy New Horizon, is currently facing shortages due to increased demand and production capacity limitations, with the drug expected to be included in the national medical insurance catalog starting January 1, 2025 [2][3]. Group 1: Company Overview - Cloudy New Horizon was established in 2017 and has listed products including Budesonide enteric-coated capsules, Ilaris, and Icotinib, targeting kidney diseases, infectious diseases, and autoimmune diseases [3]. - As of July 15, 2023, the total market capitalization of Cloudy New Horizon is approximately HKD 23.6 billion [3]. Group 2: Product Details - Budesonide enteric-coated capsules are the first drug globally for the treatment of IgA nephropathy and act as an immunomodulator targeting intestinal mucosal B cells [3]. - The drug was approved for domestic marketing in May 2024 and is included in the 2024 version of the national medical insurance catalog, specifically for adult patients with primary IgA nephropathy at risk of progression [3]. Group 3: Financial Performance - In 2024, Cloudy New Horizon reported revenue of CNY 707 million, representing a year-on-year increase of 461%, primarily driven by rapid sales growth of the antibiotic Ilaris and the launch of Budesonide enteric-coated capsules [4]. - The company incurred a net loss of CNY 1.041 billion in the same year, largely due to one-time, non-recurring impairment losses related to intangible assets associated with mRNA COVID-19 vaccines [4].

Group 1 - The Hong Kong stock market for innovative drugs has seen significant gains, with companies like Bohan Bio rising over 17%, and other firms such as Sihuan Pharmaceutical and Sanofi Biotech also experiencing substantial increases [1] - Various ETFs related to innovative drugs have also performed well, with multiple funds rising over 2% and others over 1.5% [1][3] Group 2 - Recent updates from the National Healthcare Security Administration indicate that several new innovative drugs have been rapidly entering hospitals, with a focus on those included in the medical insurance directory by May 2025 [5][6] - Notable drugs showing fast hospital admission growth include those from Kangfang Biotech and Shanghai Yizhong, among others [6] Group 3 - Citigroup's research report highlights a significant increase in market interest in the healthcare sector, particularly in innovative drugs, with expectations for the CXO sector to gain attention due to improved fundamentals and attractive valuations [7] - The report also mentions that WuXi AppTec's revenue for fiscal year 2024 is projected to reach 39.24 billion RMB (approximately 5.4 billion USD), with a growth forecast of 10%-15% for 2025 [7] Group 4 - According to CICC's research, China's innovative drug sector is transitioning into a phase of gradual innovation, gaining international competitiveness [8] - The report emphasizes that the domestic innovative drug industry is expected to reach a turning point by 2025, shifting from capital-driven growth to profit-driven growth [8]

Investment Rating - The report maintains an investment rating of "Leading the Market - A" [9] Core Insights - The report highlights that several newly included innovative drugs in the medical insurance directory are rapidly entering hospitals, with significant growth in the number of drugs entering hospitals by the end of May 2025 compared to April 2025 [2][22] - The report notes that the new drug sector has shown a strong performance, with notable increases in stock prices for companies such as Beihai Kangcheng (114.5%), Frontier Biotech (41.4%), and Junsheng Tai (29.4%) during the week of July 7 to July 13, 2025 [1][18] Summary by Sections Weekly New Drug Market Review - From July 7 to July 13, 2025, the top five companies in the new drug sector by stock price increase were Beihai Kangcheng (114.5%), Frontier Biotech (41.4%), Junsheng Tai (29.4%), Kaituo Pharmaceutical (20.7%), and Yongtai Biotech (20.1%) [1][18] - The top five companies by stock price decrease were Yiming Anke (-19.4%), Shenzhou Cell (-13.4%), Ascentage Pharma (-10.0%), Lepu Biotech (-8.9%), and Rongchang Biotech (-8.8%) [1][18] Key Analysis of the New Drug Industry - The National Medical Insurance Administration updated the hospital admission data for innovative drugs included in the medical insurance directory as of the end of May 2025, indicating rapid hospital admissions for several newly included domestic innovative drugs [2][22] - Notable drugs with fast admission growth included Kangfang Biotech's Cardunilumab and Ivorisumab, Shanghai Yizhong's Paclitaxel Micelle, and Zecjin Pharmaceutical's Recombinant Human Thrombin [2][22] New Drug Approval and Acceptance Status - Four new drug or new indication applications were approved this week, including Ascentage Pharma's Lisatoclax tablets and Zhejiang Tianyuan's quadrivalent influenza virus split vaccine [26][27] - Ten new drug applications were accepted, including Dali Yingjie’s Docetaxel Injection and Zhaoke Pharmaceutical's Atropine Sulfate Eye Drops [26][28] Clinical Application Approval and Acceptance Status - This week, 43 new drug clinical applications were approved, and 20 new drug clinical applications were accepted [4][28]